{
  "id": 6534455,
  "title": "Alumis director Akkaraju buys $5.8m, sells $1m of ALMS shares",
  "url": "https://urgent.news/2026/09/10/alumis-director-akkaraju-buys-5-8m-sells-1m-of-alms-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-10T03:31:02.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/alumis-director-akkaraju-buys-58m-sells-1m-of-alms-shares-93CH-4894919"
  },
  "original_language": "en",
  "account": "Akkaraju, a director at Alumis Inc., made significant share transactions in September 2026. He bought shares worth $4.9 million at prices between $11.02 and $11.60 per share, and then sold shares worth $1 million at prices ranging from $10.38 to $10.91 per share. The transactions were indirect through two investment funds, Samsara BioCapital, L.P. and Samsara Opportunity Fund, L.P. The sale resulted in a short-swing profit liability that Akkaraju agreed to give to Alumis Inc. Notably, ALMS stock has fallen 65% over the past six months despite a 128% gain over the previous year, trading at $9.80 with a 52-week high of $31.35. Additionally, Alumis Inc. reported negative results from its Phase 2b trial for a lupus drug, leading to a downgrade from Guggenheim and price target reductions from Morgan Stanley and Wells Fargo. Despite these setbacks, the company plans to explore promising results from a subgroup in Phase III development.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}